Theravance CEO Rick Winningham Sells 22,353 Shares (THRX)
Theravance (NASDAQ:THRX) CEO Rick Winningham sold 22,353 shares of the stock on the open market in a transaction dated Thursday, September 12th. The shares were sold at an average price of $40.03, for a total value of $894,790.59. Following the completion of the transaction, the chief executive officer now directly owns 690,106 shares in the company. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Theravance (NASDAQ:THRX) in a research note to investors on Friday, August 30th. They now have a $38.00 price target on the stock. Separately, analysts at Stifel Nicolaus cut their price target on shares of Theravance (NASDAQ:THRX) from $54.00 to $52.00 in a research note to investors on Friday, July 26th. They now have a “buy” rating on the stock. Finally, analysts at Morgan Stanley initiated coverage on shares of Theravance (NASDAQ:THRX) in a research note to investors on Monday, July 22nd. They set an “underweight” rating and a $13.00 price target on the stock.
One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $35.50.
Theravance (NASDAQ:THRX) traded down 1.19% during mid-day trading on Friday, hitting $40.70. 1,055,148 shares of the company’s stock traded hands. Theravance has a 52-week low of $19.61 and a 52-week high of $42.96. The stock has a 50-day moving average of $37.12 and a 200-day moving average of $33.27. The company’s market cap is $4.365 billion.
Theravance (NASDAQ:THRX) last announced its earnings results on Thursday, July 25th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.46) by $0.09. The company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.43 million. During the same quarter in the prior year, the company posted ($0.42) earnings per share. The company’s quarterly revenue was down 7.2% on a year-over-year basis. On average, analysts predict that Theravance will post $-1.96 earnings per share for the current fiscal year.
Theravance, Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.